Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoSil MedicalASX:OSL +2.89%39 Days Sales Outstanding is 478.86 as of Dec. 2025, which is 864% above its 10-year median of 49.69. GuruFocus rates ASX:OSL with a GF Score™ of 39/100 and a GF Value™ of A$2.92 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 811 Medical Devices & Instruments companies, OncoSil Medical ranks worse than 98.03% on this metric.
The historical rank and industry rank for OncoSil Medical's Days Sales Outstanding or its related term are showing as below:
ASX:OSL'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.19 Med: 49.69 Max: 498.3
Current: 498.3
During the past 13 years, OncoSil Medical's highest Days Sales Outstanding was 498.30. The lowest was 36.19. And the median was 49.69.
ASX:OSL's Days Sales Outstanding is ranked worse than 98.03% of 811
companies
in the Medical Devices & Instruments industry
Industry Median: 65.18
vs ASX:OSL: 498.30
OncoSil Medical's Days Sales Outstanding
increased
from Dec. 2024 (423.65) to Dec. 2025 (478.86).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
OncoSil Medical (ASX:OSL) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
OncoSil Medical Days Sales Outstanding Related Terms
OncoSil Medical Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for OncoSil Medical's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:OSL vs ABT, SYK, MDT: Days Sales Outstanding Comparison
For the Medical Devices subindustry, OncoSil Medical's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoSil Medical Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where OncoSil Medical's Days Sales Outstanding falls into.
OncoSil Medical Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 478.86 mean?
OncoSil Medical (ASX:OSL) has a Days Sales Outstanding of 478.86 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on OncoSil Medical and its competitors. This is 864% above median its historical median of 49.69. Over the past decade, OncoSil Medical's Days Sales Outstanding has ranged from 36.19 to 498.30. According to the industry distribution chart, OncoSil Medical ranks #795 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 98%.
Is OncoSil Medical's Days Sales Outstanding too high?
OncoSil Medical's current Days Sales Outstanding of 478.86 is 864% above median its 10-year median of 49.69. Over the past 10 years, this metric has ranged from a low of 36.19 to a high of 498.30. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.18. OncoSil Medical's value of 478.86 is 634.7% above this industry median. Based on the distribution chart, OncoSil Medical ranks #795 out of 811 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, OncoSil Medical has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's Days Sales Outstanding compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OncoSil Medical ranks #795 out of 811 companies for Days Sales Outstanding. This places OncoSil Medical in the lower half of its industry. The industry median Days Sales Outstanding is 65.18. OncoSil Medical's value of 478.86 is 634.7% above this benchmark. Historically, OncoSil Medical's own Days Sales Outstanding has ranged from 36.19 to 498.30 over the past decade. While the company's 10-year median is 49.69 vs. the industry median of 65.18, OncoSil Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.18, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OncoSil Medical's current Days Sales Outstanding of 478.86 is 634.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on OncoSil Medical and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoSil Medical's current Days Sales Outstanding is 478.86, which is 864% above median its own 10-year median of 49.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.92, compared to a current price of A$1.25 — trading 57.4% below its estimated fair value. The current Days Sales Outstanding is 478.86, which is 864% above median its 10-year median of 49.69 and 634.7% above the Medical Devices & Instruments industry median of 65.18. OncoSil Medical's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current Days Sales Outstanding is 478.86 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoSil Medical (ASX:OSL) Overvalued in 2026?
Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued.
The current stock price of A$1.25 is trading 57.4% below its estimated GF Value™ of A$2.92.
GuruFocus considers OncoSil Medical to be Possible Value Trap.
Key valuation signals for ASX:OSL:
Days Sales Outstanding: 478.86 (864% above median its 10-year median of 49.69)
GF Value™: A$2.92 vs. price of A$1.25 (57.4% below fair value)
Industry Position: 634.7% above the Medical Devices & Instruments median (#795 of 811)
No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
39GF Score
Get the complete analysis for ASX:OSL
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSL has been successfully added to your 
